Management strategies for recurrent platinum-resistant ovarian cancer
Abstract
Although ovarian cancer is often a chemosensitive malignancy, patients who are resistant to platinum-based chemotherapy represent a therapeutic challenge. Currently, the only drugs that are US FDA approved to treat this subset of patients are paclitaxel, pegylated liposomal doxorubicin (PLD) and topotecan. The response rates with these agents is in the 10-15% range and overall survival is around 12 months. Other drugs that have shown some activity in platinum-resistant ovarian cancer include the taxane analogues, oral etoposide, pemetrexed and bevacizumab. Unfortunately, randomized phase III trials of second-line chemotherapy in patients with platinum-resistant ovarian cancer have not shown an advantage over existing therapy with respect to progression-free survival or overall survival. The only trial that has reported a significant progression-free survival advantage over standard therapy is a randomized phase II trial of PLD with or without EC145, a folate-linked vinca alkaloid. Final survival results of this trial are pending.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The RAISE trial reported a 2-year survival advantage of 5-10% for ramucirumab versus placebo.
“In Table 6, the scoring for ramucirumab vs placebo in the RAISE trial should acknowledge the reported 2-year survival advantage of 5-10%.”
The citation lists haven’t been fetched yet
References 94 · Cited by 152
- Authors
- Naumann, R. W., & Coleman, R. L.
- Affiliations
- Carolinas Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Naumann, R. Wendel
- Venue
- Drugs
- Published
- 2011-07
- Volume
- 71
- Issue
- 11
- Pages
- 1397-1412
- ISSN
- 0012-6667 (ISSN-L)
- OpenAlex
- W2006122393
- Cited by
- 152
- References
- 94
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 3 · 2023: 14 · 2022: 4 · 2021: 13 · 2020: 16 · 2019: 9 · 2018: 10 · 2017: 9 · 2016: 12 · 2015: 14 · 2014: 17 · 2013: 17 · 2012: 8
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ovarian Cancer Research Fund
- Abbott Laboratories
- European Society for Medical Oncology
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- platinum-resistant ovarian cancer, recurrent ovarian cancer, second-line chemotherapy, paclitaxel, pegylated liposomal doxorubicin, topotecan, taxane analogues, etoposide, pemetrexed, bevacizumab, progression-free survival, overall survival
- MeSH terms
- Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, Female, Humans, Ovarian Neoplasms, Platinum, Recurrence, Drug Resistance, Neoplasm, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
